IL17A and psoriasis: This study revealed that topical administration of astilbin at a lower dose targeted the TLR7/8 signalling pathway, subsequently inhibiting Th17/IL‐17A‐induced immune responses and excessive keratinocyte proliferation to ameliorate IMQ‐induced psoriasis‐like skin lesions in SKH‐1 mice.